Clinical Effects of Short-Term Oral Budesonide on the Hypothalamic-Pituitary-Adrenal Axis in Dogs With Inflammatory Bowel Disease

2004 ◽  
Vol 40 (2) ◽  
pp. 120-123 ◽  
Author(s):  
Joshua W. Tumulty ◽  
John D. Broussard ◽  
Jörg M. Steiner ◽  
Mark E. Peterson ◽  
David A. Williams
Keyword(s):  
Inflammatory Bowel Disease ◽  
Specific Gravity ◽  
Hpa Axis ◽  
Bowel Disease ◽  
Serum Alkaline Phosphatase ◽  
Urine Specific Gravity ◽  
Clinical Effects ◽  
Hypothalamic Pituitary Adrenal ◽  
Oral Preparation ◽  
Inflammatory Bowel

Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m2, was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.

scholarly journals The effect of orally administered Budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease

2017 ◽  
Vol 62 (No. 5) ◽  
pp. 261-268
Author(s):  
A. Rychlik ◽  
M. Nowicki ◽  
A. Kolodziejska-Sawerska ◽  
M. Szweda
Keyword(s):  
Inflammatory Bowel Disease ◽  
Alkaline Phosphatase ◽  
Hpa Axis ◽  
Bowel Disease ◽  
Adrenocorticotropic Hormone ◽  
Chemical Properties ◽  
Activity Levels ◽  
Hypothalamic Pituitary Adrenal ◽  
Inflammatory Bowel ◽  
Biochemical Analyses

The aim of this study was to evaluate the effect of Budesonide on the hypothalamic-pituitary-adrenal (HPA) axis in dogs with inflammatory bowel disease. The effect of orally administered Budesonide (Entocort) on the HPA axis was analysed in 21 dogs with inflammatory bowel disease. Biochemical analyses were carried out to evaluate the activity levels of alanine aminotransferase, asparagine aminotransferase, alkaline phosphatase, cortisol and endogenous adrenocorticotropic hormone. Urine samples were collected from each patient before the study and after 30 days of the experiment to determine the composition and the physical and chemical properties of urine sediments. Considerably lower serum concentrations of cortisol and endogenous adrenocorticotropic hormone were observed after 30 days of treatment. A significant increase in alkaline phosphatase levels was noted on Day 30. In the studied dogs, the drop in HPA axis activity was correlated with side effects associated with the administered glucocorticosteroid (polyuria, polydipsia). In conclusion, we have shown that oral administration of Budesonide to dogs diagnosed with inflammatory bowel disease significantly suppressed the activity of the HPA axis.

scholarly journals Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 414 ◽  
Author(s):  
Helena Rolandsdotter ◽  
Kerstin Jönsson-Videsäter ◽  
Ulrika L. Fagerberg ◽  
Yigael Finkel ◽  
Michael Eberhardson
Keyword(s):  
Inflammatory Bowel Disease ◽  
Enteral Nutrition ◽  
Bowel Disease ◽  
Induction Treatment ◽  
Clinical Effects ◽  
Diagnostic Colonoscopy ◽  
Exclusive Enteral Nutrition ◽  
Complete Clinical Remission ◽  
Before And After ◽  
Inflammatory Bowel

Exclusive Enteral Nutrition (EEN) is the first-line treatment in children with Crohn’s disease (CD) for induction of remission. However, the mode of action remains conjectural. The aim of this study was to investigate whether the effect of EEN is paralleled by changes in the mucosal cytokine profiles (MCP). Twelve children with new onset inflammatory bowel disease (IBD) received induction treatment with a polymeric EEN. We assessed clinical, endoscopic and histologic scoring before and after EEN. Twelve colonic cytokines were analyzed by Polymerase Chain Reaction (PCR) in six of the IBD patients at onset and after EEN as well as in six non-IBD control children at the diagnostic colonoscopy. Twelve children completed 6 weeks of EEN, except from one child who completed 4 weeks. At the control colonoscopy, 83% were in complete clinical remission. Changes were found in the MCPs of individual patients after EEN. In particular, children with IBD showed significantly higher values of Interleukin (IL)-12β (p = 0.008) and IL-23α (p = 0.02) compared to non-IBD controls at the diagnostic colonoscopy. Furthermore, an overall change in proinflammatory cytokines was noted in the IBD-group after treatment. Further studies are warranted to understand the role of EEN in MCP.

scholarly journals Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants

Genes ◽  
2019 ◽  
Vol 10 (4) ◽  
pp. 277 ◽  
Author(s):  
Marianna Lucafò ◽  
Gabriele Stocco ◽  
Stefano Martelossi ◽  
Diego Favretto ◽  
Raffaella Franca ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Efficacy ◽  
Bowel Disease ◽  
Genetic Variants ◽  
Young Patients ◽  
Linear Mixed Effect Model ◽  
Clinical Effects ◽  
Dose Ratio ◽  
Mixed Effect ◽  
Inflammatory Bowel

The contribution of candidate genetic variants involved in azathioprine biotransformation on azathioprine efficacy and pharmacokinetics in 111 young patients with inflammatory bowel disease was evaluated. Azathioprine doses, metabolites thioguanine-nucleotides (TGN) and methylmercaptopurine-nucleotides (MMPN) and clinical effects were assessed after at least 3 months of therapy. Clinical efficacy was defined as disease activity score below 10. Candidate genetic variants (TPMT rs1142345, rs1800460, rs1800462, GSTA1 rs3957357, GSTM1, and GSTT1 deletion) were determined by polymerase chain reaction (PCR) assays and pyrosequencing. Statistical analysis was performed using linear mixed effects models for the association between the candidate variants and the pharmacological variables (azathioprine doses and metabolites). Azathioprine metabolites were measured in 257 samples (median 2 per patient, inter-quartile range IQR 1-3). Clinical efficacy at the first evaluation available resulted better in ulcerative colitis than in Crohn’s disease patients (88.0% versus 52.5% responders, p = 0.0003, linear mixed effect model, LME). TGN concentration and the ratio TGN/dose at the first evaluation were significantly higher in responder. TPMT rs1142345 variant (4.8% of patients) was associated with increased TGN (LME p = 0.0042), TGN/dose ratio (LME p < 0.0001), decreased azathioprine dose (LME p = 0.0087), and MMPN (LME p = 0.0011). GSTM1 deletion (58.1% of patients) was associated with a 18.5% decrease in TGN/dose ratio and 30% decrease in clinical efficacy. GSTA1 variant (12.8% of patients) showed a trend (p = 0.049, LME) for an association with decreased clinical efficacy; however, no significant effect on azathioprine pharmacokinetics could be detected. In conclusion, GSTs variants are associated with azathioprine efficacy and pharmacokinetics.

Sign in / Sign up

Export Citation Format

Share Document